share_log

Benuvia To Go Public Via SPAC Deal With Pono Capital, Deal Valued At $440M

Benuvia To Go Public Via SPAC Deal With Pono Capital, Deal Valued At $440M

Benuvia 將通過 SPAC 與 Pono Capital 的交易上市,交易價值4.4億美元
Benzinga Real-time News ·  2022/03/18 06:07
Benuvia, a leading drug developer focused on pharmaceutical cannabinoids has entered into a definitive business combination agreement with Pono Capital Corp (NASDAQ:PONO) The transaction implies a combined company pro forma enterprise value of $440 million Benuvia owns SYNDROS®, the FDA approved dronabinol (THC) oral solution, CII, which is approved for chemotherapy-induced nausea and vomiting in cancer patients and loss of appetite in AIDS patients who have lost weight, and is pursuing three additional INDs based on the same formulation as SYNDROS® Benuvia manufactures active pharmaceutical ingredients in its 83,000 square foot manufacturing facility that is permitted by the US DEA...
貝努維亞, 一家專注於藥物大麻素的領先藥物開發商 已與之簽訂了最終的業務合併協議 波諾 資本公司 (納斯達克股票代碼:PONO) 該交易意味着合併後的公司預計企業價值爲 4.4 億美元n 貝努...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論